---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-003908"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:17:58.736536+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eyenovia reacquires MicroPine rights from B&L for $2M cash + $3M stock

## Summary
- Reacquired U.S. and Canada rights to MicroPine (late-phase III pediatric progressive myopia) from Bausch + Lomb Ireland.
- Consideration: $2M upfront cash + $3M in common stock + low single-digit royalty on net sales in U.S./Canada.
- MicroPine uses Optejet dispenser; market estimated at ~$2B annually in the U.S. by Review of Myopia Management.
- Ongoing CHAPERONE trial to be transferred; Eyenovia plans to meet with FDA to explore expedited development path.
- No impact on partnership with Arctic Vision covering Greater China and South Korea.

## SEC filing metadata
- accession: 0001104659-24-003908
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/0001104659-24-003908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/tm243285d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-003908
- JSON: https://secwatch.observer/filing/0001104659-24-003908.json
- Plain text: https://secwatch.observer/filing/0001104659-24-003908.txt

## Key facts
- Material Agreements
  HYPERION DEFI, INC. entered into Letter Agreement with Bausch + Lomb Ireland Limited valued at cash and common stock consideration; $2 million upfront cash payment; $3 million in common stock; lo (effective 2024-01-12).
  - Action: entry
  - Agreement: license
  - Counterparty: Bausch + Lomb Ireland Limited
  - Value: cash and common stock consideration; $2 million upfront cash payment; $3 million in common stock; lo
  - Effective: 2024-01-12
  source text: On January 12, 2024, after successful negotiations between Eyenovia and B&L regarding the pediatric progressive myopia program, B&L and Eyenovia entered into a Letter Agreement (the “Letter Agreement”), pursuant to which Eyenovia will reacquire the rights to this program.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/0001104659-24-003908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.